New Data Shows Canadians Are Informed About Fertility Ahead of Awareness Week
TORONTO, April 07, 2025--(BUSINESS WIRE)--As Fertility Awareness Week approaches, new data from four leading fertility clinics across the country, Generation Fertility, Grace Fertility, Heartland Fertility, and Ottawa Fertility Centre, reveals that Canadians are increasingly informed about fertility realities. The survey, conducted among members of the Angus Reid Forum, suggests that awareness campaigns are driving positive action, dispelling long-standing myths around reproductive health.
Infertility impacts one in six Canadians1, and these findings key insights into conception, gender, and age to empower Canadians to make informed family-planning decisions.
Key Findings
Canadians Have Realistic Grasp of Conception Timelines - More than half (54%) of Canadians correctly expect conception to take up to six months, and the majority (83%) anticipate pregnancy within a year.
Canadian perception is in line with global scientific findings, showing cumulative conception rates of approximately 75% after six months2.
Fertility Not Just a Women's Issue – Encouragingly, 65% of Canadians recognize that fertility challenges affect both men and women equally.
This data aligns with global fertility research, indicating that infertility is equally attributed to male factors, female factors, and unexplained causes in one-third of couples.
The Fertility Wake-Up Call: 40 is Not the New 30 - Nearly half (48%) of Canadians believe people should start thinking about family planning between 25-30, with men (25%) more likely than women (18%) to believe fertility awareness should begin even earlier.
Consistent with global data, this finding shows women's fertility does decline gradually but significantly starting around age 32, with a more rapid decrease after age 37.
"Canadians are more informed than ever before about fertility, and while we've come a long way, there is still progress to be made," says Dr. Michael Hartman, Fertility Specialist and Medical Director at Generation Fertility. "While general guidelines suggest trying for six months to a year depending on age, we at Generation Fertility suggest that Canadians seek help sooner rather than later because time is crucial if a problem exists."
Provincial Highlights: Regional Awareness Trends
Ontarians Recognize the Realities of Conception
Over half (51%) of Canadians expect conception to occur within the first six months of trying, and 82% expect it will take up to a year. While many Ontarians still anticipate being able to get pregnant relatively quickly, awareness efforts are helping Canadians understand the reality.
"Over our 30 years of providing fertility care and research in Canada, we have seen progress in fertility awareness regarding conception times - these statistics reflect that. It is encouraging to see some patients seeking care earlier, but there is still progress to be made here. Not only does earlier access to care allow for better counselling around options and time to consider these options, but it improves the chance of success with either fertility preservation or fertility treatments to optimize the ability to achieve a person's overall family building goals," says Dr. Jenna Gale, Fertility Specialist at Ottawa Fertility Centre.
British Columbians Acknowledge Male Fertility Factors
In British Columbia., 62% of residents correctly recognize that infertility is not gender-specific. While gaps in knowledge persist, 38% still primarily attribute fertility challenges to women, and this awareness marks a positive shift in understanding the role of male fertility.
"The age-old myth that women bear most of the responsibility for infertility is false. It is key for both partners to undergo fertility assessments to ensure they are addressing all potential factors affecting conception, rather than focusing on one partner's perceived responsibility." - Dr. Ghadeer Akbar, Fertility Specialist at Grace Fertility. "That being said, as women age, egg quality naturally declines. It's never too early to consider egg freezing to preserve your fertility.
Manitobans Are Prioritizing Early Family Planning
Notably, 41% of Manitobans believe in considering family planning between ages 25-30, indicating a proactive approach to fertility, ensuring timely assessments and informed decision-making.
"As a fertility specialist, I've seen Canadians become more aware that pregnancy takes time, especially as women age. Despite greater awareness of fertility challenges, women often bear the weight of guilt and self-blame. I hope greater fertility awareness helps people see that they are not alone, and that it's not their fault," says Dr. Stephanie Appleby, Fertility Specialist at Heartland Fertility. "If you suspect reproductive issues, see a specialist. It's never too soon to take control of your fertility."
Awareness in Action
These findings confirm that national fertility awareness efforts are shifting public perception in a meaningful way. While there is still work to be done, the data demonstrates that Canadians are increasingly well-informed, making educated decisions about their reproductive health.
Methodology:
These are the findings of a study/survey conducted by four clinics within The Fertility Partners network including Generation Fertility, Grace Fertility, Ottawa Fertility Centre, and Heartland Fertility from March 3rd to 4th, 2025 among a representative sample of 1,563 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/- 2.5 percentage points, 19 times out of 20.
1 WHO
2 National Library of Medicine
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407721097/en/
Contacts
MEDIA Lindsay Silverberglindsay@chimera-collective.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
B.C. ostrich farm loses court bid to prevent avian flu cull
OTTAWA — The Federal Court of Appeal has rejected a bid by a British Columbia ostrich farm to prevent the culling of its flock that had been infected with avian flu. The court denied an appeal by Universal Ostrich Farms to allow an application for judicial review of the planned cull of about 400 birds, which was ordered by the Canadian Food Inspection Agency. The appeal court also rejected an application to bring new evidence in the case. "In so concluding, we recognize that our decision might lead to the death of over 400 ostriches owned by the appellant, an outcome that would doubtless be very difficult, both financially and emotionally, for the appellant's principals," the ruling posted Thursday said. "While we have considerable sympathy for them, the law we are bound to apply inevitably leads to the conclusion that this appeal must be dismissed." The ruling said the "stamping out" policy of the CFIA, in which infected poultry flocks are killed entirely, is reasonable, and that criteria to apply it had been met in the case of the farm in Edgewood, B.C. The planned cull had drawn opposition from United States officials, including Health Secretary Robert F. Kennedy Jr. Universal Ostrich Farm spokeswoman Katie Pasitney, whose mother co-owns the farm, called the news 'devastating' in a post online. She said the decision meant 'that at any moment, the Canadian Food Inspection Agency could come and kill our healthy ostriches.' Pasitney said the farm will apply for a stay of the ruling next week, and she appealed for supporters to go to the farm and "sit with animals that need protection." "Absolutely zero violence. Peaceful only," she added. She said the farm would open its gates to the public this weekend. 'These animals are not just livestock. They are living beings that have thrived against all odds. They are a symbol of resilience, of natural immunity, and of what's possible when we stand up against broken policies that destroy life instead of protecting it." The ruling says it's not the role of the court to grant exemptions from governmental policy. "Rather, our sole role is to determine whether the decisions at issue in this appeal were reasonable in accordance with the deferential standard of review set out in the case law of the Supreme Court of Canada, this court, and other Canadian courts," it says. "Because the stamping-out policy, which underlies the two decisions, the notice to dispose, and the exemption denial, are all reasonable in accordance with that case law, we have unanimously concluded that this appeal cannot succeed." Sixty-nine of the flock died of highly pathogenic avian flu in December and January. But the farm's owners said the surviving birds should be spared, in part because of their scientific value. Kennedy wrote to the CFIA offering to jointly study the birds, while former TV personality Dr. Mehmet Oz, now the administrator of the U.S. Centers for Medicare and Medicaid Services, said he would be willing to house them at his ranch in Florida. This report by The Canadian Press was first published Aug. 21, 2025. The Canadian Press
Yahoo
3 hours ago
- Yahoo
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio
Business Wire
5 hours ago
- Business Wire
CareDx to Participate in Wells Fargo Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, Massachusetts, on September 5, 2025, at 8:00 AM ET. A live and archived webcast of the presentation will be available on the 'Events and Presentations' section of the CareDx investor relations website at About CareDx – The Transplant Company CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit
